Expert insights on Hodgkin’s lymphoma development in an activated PI3K delta syndrome patient undergoing leniolisib treatment
Activated PI3K delta syndrome (APDS) is a primary immunodeficiency that is caused by mutations in the PI3K signalling pathway resulting in either gain-of-function or loss-of-function phenotypes of APDS 1 and 2. Malignancy is one of the most serious complications associated with APDS patients, with t...
Saved in:
| Main Authors: | Francesca Conti, Mattia Moratti, Elena Sabattini, Pier Luigi Zinzani |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-01-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2024.1517543/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
FDA approves leniolisib (Joenja) as the first treatment for APDS: A breaththrough in the field of immunology
by: Muhammad Talha, et al.
Published: (2024-01-01) -
Refractory/Relapsed Classic Hodgkin Lymphoma Mimicking Disseminated Tuberculosis
by: Mohamed Nazem Alibrahim, et al.
Published: (2025-05-01) -
Tumor‐associated macrophages: potential role in skeletal involvement in classic Hodgkin lymphoma
by: Maja Dam Andersen, et al.
Published: (2025-07-01) -
The immune cell dynamics in the peripheral blood of cHL patients receiving anti-PD1 treatment
by: Vanessa Cristaldi, et al.
Published: (2025-03-01) -
Tumor-microenvironment and molecular biology of classic Hodgkin lymphoma in children, adolescents, and young adults
by: Tomohiro Aoki, et al.
Published: (2025-05-01)